EUCTR2009-017736-41-DK进行中（未招募）1 期
Fibrinogen-koncentrat som initial behandling ved postpartum blødning - [FIB·PPH]-studiet
Anæstesiologisk Afd. Herlev Hospital0 个研究点目标入组 245 人开始时间: 2010年2月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 245
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •PPH defineret som blødning fra uterus og/eller fødselskanalen opstået indenfor de første 24
- •timer efter fødsel. Alder = 18 år. Samtykke fra patient eller forsøgsværge.
- •Vaginal forløsning: Ved indikation for ét af følgende postnatale indgreb udført på operationsgangen med
- •anæstesiologisk assistance:
- •i.Ved estimeret blodtab = 500 ml og indikation for manuel placentafjernelse.
- •ii.Ved manuel eksploration af uterus på grund af blødning efter placentas fødsel.
- •Forløsning ved sectio: Peroperativt blodtab =1000 ml.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patienter med kendt medfødt koagulationsdefekt.
- •Patienter, der præpartum er i behandling med antitrombotiske midler: AK- behandling (Warfarin), trombocythæmmende midler (Clopidogrel og Acetylsalicylsyre), lavmolekulært heparin (LMWH). Omfattende terapeutiske såvel som profylaktiske doser.
- •Patienter med en prægraviditetsvægt
- •Patienter der på forhånd modsætter sig blodtransfusion.
研究者
相似试验
已完成
不适用
Application of fibrinogen concentrate (Fibrinogen HT) to uncontrollable massive bleedingMassive bleeding during 1)Pregnancy and delivery 2)Cardiovascular surgery 3)Gastrointestinal (including hepato-biliary-pancreatic) surgeryJPRN-UMIN000022666Kagoshima University Hospital, Division of blood transfusion medicine and cell therapy26
进行中（未招募）
1 期
se of fibrinogen in the treatment of bleeding in thrombopenic patients after intensive chemotherapy refractory to platelet transfusio- Major patient- Patient with malignant hemopathy requiring intensive chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation- Grade = 1 hemorrhagic symptom according to WHO - WHO classification- Body weight between 38 and 78 kg- Patient presenting with a platelet refractory state defined according to the Corrected Count Increment (CCI)- Patient affiliated to a social security schemeMedDRA version: 21.1Level: LLTClassification code 10066481Term: Hematological malignancySystem Organ Class: 100000004864EUCTR2021-000990-10-FRInstitut de Cancérologie Lucien Neuwirth10
招募中
2 期
Efficacy and safety of early fibrinogen concentrate substitution therapy for severe trauma patients receiving massive transfusions: prospective single arm clinical trialsevere traumaJPRN-UMIN000010294Saitama Medical Center, Saitama Medical University30
尚未招募
3 期
The administration of fibrinogen concentrate (a component of blood involved in clotting process) to be given to those women who, after delivery of babies, develop severe bleeding to establish if this drug will prevent further blood loss or reduce the volume of blood loss.Post partum haemorrhageReproductive Health and Childbirth - Childbirth and postnatal careBlood - Clotting disordersACTRN12614000691640Auckland City Hospital245
已完成
不适用
Effect of prophylactic fibrinogen on post operative bleeding in coronary artery bypass graft surgeryHemorrhage.Hemorrhage, not elsewhere classifiedIRCT201011085140N1Tehran University of Medical Sciences60